Abstract
Cisplatin is a drug widely used in chemotherapy that frequently causes severe renal dysfunction. Organic transporters have an important role to control the absorption and excretion of cisplatin in renal cells. Deletion and blockage of kinin B1 receptor has already been show to protect against cisplatin-induced acute kidney injury. To test whether it exerts its protective function by modulating the organic transporters in kidney, we studied kinin B1 receptor knockout mice and treatment with a receptor antagonist at basal state and in presence of cisplatin. Cisplatin administration caused downregulation of renal organic transporters; in B1 receptor knockout mice, this downregulation of organic transporters in kidney was absent; and treatment by a B1 receptor antagonist attenuated the downregulation of the transporter MATE-1. Moreover, kinin B1 receptor deletion and blockage at basal state resulted in higher renal expression of MATE-1. Moreover we observed that kinin B1 receptor deletion and blockage result in less accumulation of platinum in renal tissue. Thus, we propose that B1 receptor deletion and blockage protect the kidney from cisplatin-induced acute kidney injury by upregulating the expression of MATE-1, thereby increasing the efflux of cisplatin from renal cells.
Similar content being viewed by others
References
Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460–464
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2:2490–2518
Thadhani R, Pascual M, Bonventre JV (1996) Acute renal failure. N Engl J Med 334:1448–1460
Morisaki T, Matsuzaki T, Yokoo K, Kusumoto M, Iwata K, Hamada A, Saito H (2008) Regulation of renal organic ion transporters in cisplatin-induced acute kidney injury and uremia in rats. Pharm Res 25:2526–2533
Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115–124
Motohashi H, Inui K (2013) Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. Aaps J 15: 581–588.
Wang L, Sweet DH (2013) Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease. Aaps J 15:53–69.
Matsuzaki T, Morisaki T, Sugimoto W, Yokoo K, Sato D, Nonoguchi H, Tomita K, Terada T, Inui K, Hamada A, Saito H (2008) Altered pharmacokinetics of cationic drugs caused by down-regulation of renal rat organic cation transporter 2 (Slc22a2) and rat multidrug and toxin extrusion 1 (Slc47a1) in ischemia/reperfusion-induced acute kidney injury. Drug Metab Dispos 36:649–654
Nies AT, Koepsell H, Damme K and Schwab M (2011) Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol:105–67.
Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pavenstadt H, Massmann V, Guckel D, Mathijssen RH, Yang W, Pui CH, Relling MV, Herrmann E, Sparreboom A (2012) Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res 18:1101–1108
Ludwig T, Riethmuller C, Gekle M, Schwerdt G, Oberleithner H (2004) Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 66:196–202
Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86:396–402
Kido Y, Matsson P, Giacomini KM (2011) Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem 54:4548–4558
Masuda Y, Inoue M, Miyata A, Mizuno S, Nanba H (2009) Maitake beta-glucan enhances therapeutic effect and reduces myelosupression and nephrotoxicity of cisplatin in mice. Int Immunopharmacol 9:620–626
Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 102:17923–17928
Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K (2009) Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 75:1280–1286
Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui K (2010) Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol 80:1762–1767
Marceau F, Bachvarov DR (1998) Kinin receptors. Clin Rev Allergy Immunol 16:385–401
Regoli D, Barabe J (1980) Pharmacology of bradykinin and related kinins. Pharmacol Rev 32:1–46
Pereira RL, Buscariollo BN, Correa-Costa M, Semedo P, Oliveira CD, Reis VO, Maquigussa E, Araujo RC, Braga TT, Soares MF, Moura IC, Malheiros DM, Filho AP, Keller AC, Camara NO (2011) Bradykinin receptor 1 activation exacerbates experimental focal and segmental glomerulosclerosis. Kidney Int 79:1217–1227
Klein J, Gonzalez J, Duchene J, Esposito L, Pradere JP, Neau E, Delage C, Calise D, Ahluwalia A, Carayon P, Pesquero JB, Bader M, Schanstra JP and Bascands JL (2009) Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. Faseb J 23:134–142.
Klein J, Gonzalez J, Decramer S, Bandin F, Neau E, Salant DJ, Heeringa P, Pesquero JB, Schanstra JP, Bascands JL (2010) Blockade of the kinin B1 receptor ameloriates glomerulonephritis. J Am Soc Nephrol 21:1157–1164
Wang PH, Campanholle G, Cenedeze MA, Feitoza CQ, Goncalves GM, Landgraf RG, Jancar S, Pesquero JB, Pacheco-Silva A, Camara NO (2008) Bradykinin [corrected] B1 receptor antagonism is beneficial in renal ischemia–reperfusion injury. PLoS ONE 3:e3050
Wang PH, Cenedeze MA, Pesquero JB, Pacheco-Silva A, Camara NO (2006) Influence of bradykinin B1 and B2 receptors in the immune response triggered by renal ischemia–reperfusion injury. Int Immunopharmacol 6:1960–1965
Estrela GR, Wasinski F, Almeida DC, Amano MT, Castoldi A, Dias CC, Malheiros DM, Almeida SS, Paredes-Gamero EJ, Pesquero JB, Barros CC, Camara NO, Araujo RC (2014) Kinin B1 receptor deficiency attenuates cisplatin-induced acute kidney injury by modulating immune cell migration. J Mol Med (Berl) 92:399–409
Estrela GR, Wasinski F, Bacurau RF, Malheiros DM, Camara NO, Araujo RC (2014) Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury. Int Immunopharmacol 22:115–119
Inui KI, Masuda S, Saito H (2000) Cellular and molecular aspects of drug transport in the kidney. Kidney Int 58:944–958
Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994–1007
Pohlen U, Rieger H, Meyer BT, Loddenkemper C, Buhr HJ, Heitland P, Koester HD, Schneider P (2007) Chemoembolization of lung metastases–pharmacokinetic behaviour of carboplatin in a rat model. Anticancer Res 27:809–815
Acknowledgements
This work was supported by FAPESP grants 2013/06207-6, 2015/20082-7 and by CAPES/PROBRAL grant 7191/15-4.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All the authors declared no competing interests.
Rights and permissions
About this article
Cite this article
Estrela, G.R., Wasinski, F., Felizardo, R.J.F. et al. MATE-1 modulation by kinin B1 receptor enhances cisplatin efflux from renal cells. Mol Cell Biochem 428, 101–108 (2017). https://doi.org/10.1007/s11010-016-2920-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-016-2920-x